About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Kidney Cancer Drug Votrient Gets FDA Nod

by Gopalan on October 22, 2009 at 10:48 AM
Font : A-A+

 Kidney Cancer Drug Votrient Gets FDA Nod

The US FDA has given its nod for Votrient (pazopanib) for treatment of advanced kidney cancer. The drug is manufacture by the London-based GlaxoSmithKline and is the sixth drug to be approved for kidney cancer since 2005.

Votrient is an oral medication that interferes with angiogenesis, the growth of new blood vessels needed for solid tumors to grow and survive.

Advertisement

Votrient is intended for people with advanced renal cell carcinoma, a type of kidney cancer in which the cancerous cells are found in the lining of very small tubes (tubules) in the kidney. In 2009, approximately 49,000 people were diagnosed with renal cell carcinoma and 11,000 people died from the disease in the US.

"The last five years have seen dramatic improvements in treatment options for patients with kidney cancer. Before 2005, the options available offered only limited effectiveness," said Richard Pazdur, director, Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research.
Advertisement

The five other drugs approved for kidney cancer and their approval dates are: Sorafenib (December 2005), Sunitinib (January 2006), Temsirolimus (May 2007), Everolimus (March 2009), and Bevacizumab (July 2009).

The safety and effectiveness of Votrient was evaluated in a 435-patient study that examined a patient's progression-free survival - the length of time, following enrollment in the study, before the tumor began growing again or before the patient died. Progression-free survival averaged 9.2 months for patients receiving Votrient compared to 4.2 months for patients who did not receive the drug.

Adverse reactions included diarrhea, high blood pressure, hair color changes, nausea, loss of appetite, vomiting, fatigue, weakness, abdominal pain and headache. Votrient can also cause severe and fatal liver toxicity. Health care professionals should order blood tests to monitor liver function before and during treatment with the drug. Since Votrient can harm a fetus, it should not be used during pregnancy.

The drug has also been associated with heart rhythm irregularities. Patients receiving Votrient should be monitored with periodic electrocardiograms, which measure heart rhythm, and blood tests to monitor electrolytes since an electrolyte imbalance can lead to an irregular heart rhythm, FDA stresses.

Source: Medindia
GPL/L
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Test Your Knowledge About Chromosomes?
Eating During Sunlight Hours Minimizes Mood Vulnerabilities
Know More About the Digestive System
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Cancer and Homeopathy Urinary Stones In Children Vesico-Ureteric Reflux Causing UTI in Children Hydronephrosis / Antenatal Counseling Signature Drug Toxicity Kidney Disease Cancer Facts Cancer Tattoos A Body Art 

Most Popular on Medindia

Sinopril (2mg) (Lacidipine) The Essence of Yoga Find a Doctor How to Reduce School Bag Weight - Simple Tips Nutam (400mg) (Piracetam) Drug Side Effects Calculator Daily Calorie Requirements Calculate Ideal Weight for Infants Indian Medical Journals Sanatogen
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Kidney Cancer Drug Votrient Gets FDA Nod Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests